Clinical trials: Differentiated Thyroid Cancer (DTC), active
Radioiodine Refractory Differentiated Thyroid Cancer
Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer
177Lu-LNC1004 Injection, a radiopharmaceutical targeting FAP, has demonstrated preliminary antitumor effect in advanced FAP-positive solid tumor patients.
- Trial name
- NCT06898437
- Testing
- 177Lu-LNC1004 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma
Decision Aid Efficacy in Low Risk Thyroid Cancer
Low-risk thyroid cancer grows very slowly. More than 99% of patients with this cancer survive for at least 5 years. There are 3 main treatment options: remove the whole thyroid, remove just the part of the thyroid with the cancer…
- Conditions
- Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma, Papillary Thyroid Carcinoma
- Trial name
- NCT07536412
- Testing
- Decision Aid
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Maryland, Baltimore
Radioiodine-refractory Differentiated Thyroid Cancer
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R…
- Trial name
- NCT07770074
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
This study measures circulating immune-signaling molecules before thyroid surgery to determine whether they differ between patients whose thyroid nodule proves to be a differentiated thyroid carcinoma and patients whose nodule…
- Conditions
- Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma, Thyroid Cancer, Thyroid Nodule
- Trial name
- THINC (NCT07907432)
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Marmara University
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Papillary Thyroid Cancer, Pediatric Cancer
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females.
- Conditions
- Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT05024929
- Testing
- Whole body scan
- Where
- 9 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Children's Hospital of Philadelphia
Differentiated Thyroid Cancer (DTC)
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the…
- Trial name
- NCT04940052
- Testing
- Dabrafenib, Trametinib
- Where
- 41 sites in United States, Argentina and 9 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Carcinoma
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
This is a non-interventional, multi center post-authorization safety study that includes all patients diagnosed as Unresectable Differentiated Thyroid Carcinoma (DTC) and treated with Sorafenib within a certain period.
- Trial name
- JPMS-DTC (NCT02185560)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 453 people
- Sponsor
- Bayer
Thyroid Cancer, Cancer of the Thyroid
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).
- Trial name
- NCT07092514
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Thyroid Cancer
Anlotinib and Benmelstobart in DTC
This study is a multicenter, open-label, phase II study to evaluate the efficacy and safety of Benmelstobart in combination with Anlotinib as a second-line treatment for locally advanced or metastatic differentiated thyroid…
- Trial name
- NCT07193186
- Testing
- Anlotinib and Benmelstobart
- Volunteers
- 23 people
- Sponsor
- Fudan University
DTC - Differentiated Thyroid Cancer
A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer
This trial consists of 2 parts, i.e., Part Ia and Ib. The Part Ia is to evaluate the safety and tolerability of a single intravenous dose of af-001 in patients with radically unresectable, recurrent, metastatic differentiated…
- Trial name
- NCT07287748
- Testing
- [211At]NaAt
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Alpha Fusion Inc.
Intermediate-to-High Risk Differentiated Thyroid Cancer
Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC
The global incidence of Differentiated Thyroid Cancer (DTC) is rising. While surgery followed by TSH suppression is the standard of care, achieving target TSH levels with levothyroxine (L-T4) monotherapy remains challenging, with…
- Trial name
- DELTA (NCT07239674)
- Testing
- desiccated thyroid extract (DTE)+levothyroxine (L-T4)
- Volunteers
- 646 people
- Sponsor
- West China Hospital
Thyroid Diseases, Thyroid Neoplasms
Thyroid Health Outcomes Registry for Surgery
THORS is a single-center ambidirectional observational cohort study conducted at Moscow Multidisciplinary Clinical Center "Kommunarka".
- Conditions
- Thyroid Diseases, Thyroid Neoplasms, Thyroid Cancer, Thyroid Nodules
- Trial name
- THORS (NCT07812779)
- Volunteers
- 3,000 people
- Sponsor
- Pirogov Russian National Research Medical University
Thyroid Cancer
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment.
- Trial name
- NCT06980103
- Testing
- Decision Aid, Usual Care
- Where
- 3 sites in United States
- Volunteers
- 408 people
- Sponsor
- Georgetown University
Differentiated Thyroid Carcinoma
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
ST-1898, a multi-targeted tyrosine kinase inhibitor, has demonstrated strong inhibitory activity for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT, etc.
- Trial name
- NCT06359847
- Testing
- ST-1898 tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Scitech-Mq Pharmaceuticals Limited
Differentiated Thyroid Cancer
Empirical Radioactive Iodine Therapy in DTC
The aim of the study is assessment the efficacy of empiric RAI therapy in DTC patients with elevated thyroglobulin levels and negative iodine scintigraphy.
- Trial name
- NCT07453225
- Testing
- Radioactive Iodine Therapy
- Volunteers
- 100 people
- Sponsor
- Assiut University
DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
Subjects: patients with postoperative local recurrent or metastatic differentiated thyroid cancer . Experimental group: Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a…
- Conditions
- DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C, Radiotherapy; Complications
- Trial name
- NCT06405217
- Testing
- Recombinant Human Thyroid Stimulating Hormone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Thyroid Cancer
Adjuvant Radiotherapy in High Risk Locally Advanced DTC
This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer.
- Trial name
- NCT06558981
- Testing
- Radiotherapy, radioiodine treatment
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Fudan University
Differentiated Thyroid Carcinoma (DTC), Neoadjuvant Therapy
Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma
This study is a single-arm, prospective investigation aimed at evaluating the efficacy of Sinibolimab combined with Lenvatinib as neoadjuvant therapy for locally advanced unresectable differentiated thyroid carcinoma in a Phase…
- Trial name
- NCT06848920
- Testing
- Immunotherapy combined with Multikinase inhibitors in neoadjuvant treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University